Quercetin lipid nanoparticles functionalized with transferrin for Alzheimer's disease.

[1]  M. J. Ramalho,et al.  Natural Compounds for Alzheimer’s Disease Therapy: A Systematic Review of Preclinical and Clinical Studies , 2019, International journal of molecular sciences.

[2]  G. Borge,et al.  Bioavailability of Quercetin in Humans with a Focus on Interindividual Variation. , 2018, Comprehensive reviews in food science and food safety.

[3]  A. Neves,et al.  Apo E-Functionalization of Solid Lipid Nanoparticles Enhances Brain Drug Delivery: Uptake Mechanism and Transport Pathways. , 2017, Bioconjugate chemistry.

[4]  Maria João Gomes,et al.  Tailoring Lipid and Polymeric Nanoparticles as siRNA Carriers towards the Blood-Brain Barrier – from Targeting to Safe Administration , 2016, Journal of Neuroimmune Pharmacology.

[5]  A. Neves,et al.  Resveratrol and Grape Extract-loaded Solid Lipid Nanoparticles for the Treatment of Alzheimer’s Disease , 2017, Molecules.

[6]  A. Neves,et al.  Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation , 2016, Drug design, development and therapy.

[7]  R. Leblanc,et al.  Crossing the blood-brain-barrier with transferrin conjugated carbon dots: A zebrafish model study. , 2016, Colloids and surfaces. B, Biointerfaces.

[8]  Sourav Bhattacharjee,et al.  DLS and zeta potential - What they are and what they are not? , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[9]  Jing Liu,et al.  Self-assembled targeted nanoparticles based on transferrin-modified eight-arm-polyethylene glycol–dihydroartemisinin conjugate , 2016, Scientific Reports.

[10]  L. Alpsoy,et al.  Superparamagnetic iron oxide conjugated with folic acid and carboxylated quercetin for chemotherapy applications , 2016 .

[11]  A. Neves,et al.  Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E , 2016, Journal of Nanobiotechnology.

[12]  A. Neves,et al.  Oxaprozin-Loaded Lipid Nanoparticles towards Overcoming NSAIDs Side-Effects , 2016, Pharmaceutical Research.

[13]  A. Neves,et al.  Solid lipid nanoparticles as a vehicle for brain-targeted drug delivery: two new strategies of functionalization with apolipoprotein E , 2015, Nanotechnology.

[14]  M. Coelho,et al.  Dual ligand immunoliposomes for drug delivery to the brain. , 2015, Colloids and surfaces. B, Biointerfaces.

[15]  H. Valizadeh,et al.  Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application. , 2015, Advanced pharmaceutical bulletin.

[16]  M. Coelho,et al.  Immunoliposomes doubly targeted to transferrin receptor and to α-synuclein , 2015, Future science OA.

[17]  R. Bruno,et al.  Endogenous and exogenous mediators of quercetin bioavailability. , 2015, The Journal of nutritional biochemistry.

[18]  Mandy B. Esch,et al.  TEER Measurement Techniques for In Vitro Barrier Model Systems , 2015, Journal of laboratory automation.

[19]  Y. Kuo,et al.  Neuroprotection against degeneration of sk-N-mc cells using neuron growth factor-encapsulated liposomes with surface cereport and transferrin. , 2014, Journal of pharmaceutical sciences.

[20]  Y. Kuo,et al.  Transferrin-grafted catanionic solid lipid nanoparticles for targeting delivery of saquinavir to the brain , 2014 .

[21]  J. Loureiro,et al.  Charged surfactants induce a non‐fibrillar aggregation pathway of amyloid‐beta peptide , 2013, Journal of peptide science : an official publication of the European Peptide Society.

[22]  P. Couraud,et al.  The hCMEC/D3 cell line as a model of the human blood brain barrier , 2013, Fluids and Barriers of the CNS.

[23]  A. Neves,et al.  Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability , 2013, International journal of nanomedicine.

[24]  Nicholas W. Smith,et al.  Dye-binding assays for evaluation of the effects of small molecule inhibitors on amyloid (aβ) self-assembly. , 2012, ACS chemical neuroscience.

[25]  S. Dall’Acqua,et al.  The Photodegradation of Quercetin: Relation to Oxidation , 2012, Molecules.

[26]  Sagar R. Mudshinge,et al.  Nanoparticles: Emerging carriers for drug delivery. , 2011, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[27]  Rishi Kapil,et al.  Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery , 2011, The Journal of pharmacy and pharmacology.

[28]  Z. Zhang,et al.  Quercetin exerts a neuroprotective effect through inhibition of the iNOS/NO system and pro-inflammation gene expression in PC12 cells and in zebrafish. , 2011, International journal of molecular medicine.

[29]  Jintanaporn Wattanathorn,et al.  Neuroprotective Effect of Quercetin Encapsulated Liposomes: A Novel Therapeutic Strategy against Alzheimer's Disease , 2010 .

[30]  Wei Feng,et al.  Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. , 2009, International journal of pharmaceutics.

[31]  R. Murthy,et al.  Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic®P85, an in vitro cell line and in vivo biodistribution studies on rat model , 2009, Journal of drug targeting.

[32]  J. Davis,et al.  Effects of the Dietary Flavonoid Quercetin Upon Performance and Health , 2009, Current sports medicine reports.

[33]  D. Butterfield,et al.  Protective effect of quercetin in primary neurons against Abeta(1-42): relevance to Alzheimer's disease. , 2009, The Journal of nutritional biochemistry.

[34]  M. Saraiva,et al.  Design and biological activity of beta-sheet breaker peptide conjugates. , 2009, Biochemical and biophysical research communications.

[35]  S. Krähenbühl,et al.  The human brain endothelial cell line hCMEC/D3 as a human blood‐brain barrier model for drug transport studies , 2008, Journal of neurochemistry.

[36]  Robert Gurny,et al.  Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[37]  Saengrawee Sutthiparinyanont,et al.  Anxiety and cognitive effects of quercetin liposomes in rats. , 2008, Nanomedicine : nanotechnology, biology, and medicine.

[38]  S. Litwin,et al.  Quercetin reduces blood pressure in hypertensive subjects. , 2007, The Journal of nutrition.

[39]  E. Park,et al.  Quercetin inhibits expression of inflammatory cytokines through attenuation of NF-κB and p38 MAPK in HMC-1 human mast cell line , 2007, Inflammation Research.

[40]  V. Darley-Usmar,et al.  Mechanism by which alcohol and wine polyphenols affect coronary heart disease risk. , 2007, Annals of epidemiology.

[41]  Byeoung-Soo Park,et al.  Effects of naturally occurring compounds on fibril formation and oxidative stress of beta-amyloid. , 2005, Journal of agricultural and food chemistry.

[42]  J. Greenwood,et al.  Blood‐brain barrier‐specific properties of a human adult brain endothelial cell line , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  R. Sabaté,et al.  Stimulatory and inhibitory effects of alkyl bromide surfactants on beta-amyloid fibrillogenesis. , 2005, Langmuir : the ACS journal of surfaces and colloids.

[44]  Chang Yong Lee,et al.  Protective effects of quercetin and vitamin C against oxidative stress-induced neurodegeneration. , 2004, Journal of agricultural and food chemistry.

[45]  M. R. Nilsson.  Techniques to study amyloid fibril formation in vitro. , 2004, Methods.

[46]  J. J. Balbach,et al.  Site-Specific Identification of Non-β-Strand Conformations in Alzheimer's β-Amyloid Fibrils by Solid-State NMR , 2003 .

[47]  Y. Song,et al.  Neuroprotective effects of antioxidative flavonoids, quercetin, (+)-dihydroquercetin and quercetin 3-methyl ether, isolated from Opuntia ficus-indica var. saboten , 2003, Brain Research.

[48]  R. Leapman,et al.  A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMR , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Ralf Langen,et al.  Structural and Dynamic Features of Alzheimer's Aβ Peptide in Amyloid Fibrils Studied by Site-directed Spin Labeling* , 2002, The Journal of Biological Chemistry.

[50]  E. Rimm,et al.  Flavonol and flavone intakes in US health professionals. , 2002, Journal of the American Dietetic Association.

[51]  E. Morgan,et al.  Transferrin and Transferrin Receptor Function in Brain Barrier Systems , 2000, Cellular and Molecular Neurobiology.

[52]  A. Törrönen,et al.  Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. , 1999, Journal of agricultural and food chemistry.

[53]  R. Müller,et al.  Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. , 1999, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[54]  A. Bast,et al.  Influence of iron chelation on the antioxidant activity of flavonoids. , 1998, Biochemical pharmacology.

[55]  R. Beavis,et al.  Fibrillogenesis of synthetic amyloid-β peptides is dependent on their initial secondary structure , 1995, Neuroscience Letters.

[56]  C. Cotman,et al.  Structure‐Activity Analyses of β‐Amyloid Peptides: Contributions of the β25–35 Region to Aggregation and Neurotoxicity , 1995 .

[57]  H. Levine,et al.  Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solution , 1993, Protein science : a publication of the Protein Society.

[58]  A. I. Dorozhko,et al.  Chelating and free radical scavenging mechanisms of inhibitory action of rutin and quercetin in lipid peroxidation. , 1989, Biochemical pharmacology.

[59]  A. Wach,et al.  Quercetin content in some food and herbal samples , 2007 .